S. John Weisnagel

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Effects of Exercise Training on Glucose Homeostasis

Normand G. Boulé, S. John Weisnagel, Timo A. Lakka et al. · Diabetes Care · 2005 · 354 citations

Education, Endocrinology, Physiology +16

The Human Obesity Gene Map: The 2004 Update

Louis Përusse, Tuomo Rankinen, Aamir Zuberi et al. · Obesity Research · 2005 · 334 citations

Life Sciences, Genetics, Human Genetics +12

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17